(Updated - September 1, 2026 7:02 AM EDT)

Canaccord analyst Edward Nash initiates coverage on Aclaris Therapeutis (NASDAQ: ACRS) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage

Piper Sandler on Aclaris Therapeutis (ACRS): 'Efficacy Differentiation Could Drive Share Re-Rate'August 31, 2026 8:52 AM